Literature DB >> 15677729

Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance?

Juan C Rubio1, Miguel A Martín, Manuel Rabadán, Félix Gómez-Gallego, Alejandro F San Juan, Juan M Alonso, José L Chicharro, Margarita Pérez, Joaquín Arenas, Alejandro Lucia.   

Abstract

The C34T mutation in the gene encoding for the skeletal muscle-specific isoform of AMP deaminase (AMPD1) is a common mutation among Caucasians (i.e., one of five individuals) that can impair exercise capacity. The purpose of this study was twofold. First, we determined the frequency distribution of the C34T mutation in a group of top-level Caucasian (Spanish) male endurance athletes (cyclists and runners, n = 104). This group was compared with randomly selected Caucasian (Spanish) healthy (asymptomatic) nonathletes (n = 100). The second aim of this study was to compare common laboratory indexes of endurance performance (maximal oxygen uptake or ventilatory thresholds) within the group of athletes depending on their C34T AMPD1 genotype. The frequency of the mutant T allele was lower (P < 0.05) in the group of athletes (4.3%) compared with controls (8.5%). On the other hand, indexes of endurance performance did not differ (P > 0.05) between athlete carriers or noncarriers of the C34T mutation (e.g., maximal oxygen uptake 72.3 +/- 4.6 vs. 73.5 +/- 5.9 ml.kg(-1).min(-1), respectively). In conclusion, although the frequency distribution of the mutant T allele of the AMPD1 genotype is lower in Caucasian elite endurance athletes than in controls, the C34T mutation does not significantly impair endurance performance once the elite-level status has been reached in sports.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677729     DOI: 10.1152/japplphysiol.01371.2004

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  20 in total

1.  C34T mutation of the AMPD1 gene in an elite white runner.

Authors:  A Lucia; M A Martin; J Esteve-Lanao; A F San Juan; J C Rubio; J Oliván; J Arenas
Journal:  Br J Sports Med       Date:  2006-03       Impact factor: 13.800

Review 2.  Endurance exercise performance: the physiology of champions.

Authors:  Michael J Joyner; Edward F Coyle
Journal:  J Physiol       Date:  2007-09-27       Impact factor: 5.182

Review 3.  Genes, environment and sport performance: why the nature-nurture dualism is no longer relevant.

Authors:  Keith Davids; Joseph Baker
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

4.  C34T mutation of the AMPD1 gene in an elite white runner.

Authors:  Alejandro Lucia; Miguel A Martin; Jonathan Esteve-Lanao; Alejandro F San Juan; Juan C Rubio; Jesús Oliván; Joaquín Arenas
Journal:  BMJ Case Rep       Date:  2009-01-23

5.  Is there an optimum endurance polygenic profile?

Authors:  Jonatan R Ruiz; Félix Gómez-Gallego; Catalina Santiago; Marta González-Freire; Zoraida Verde; Carl Foster; Alejandro Lucia
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

Review 6.  Genes for elite power and sprint performance: ACTN3 leads the way.

Authors:  Nir Eynon; Erik D Hanson; Alejandro Lucia; Peter J Houweling; Fleur Garton; Kathryn N North; David J Bishop
Journal:  Sports Med       Date:  2013-09       Impact factor: 11.136

7.  AMP deaminase deficiency in skeletal muscle is unlikely to be of clinical relevance.

Authors:  Frank Hanisch; Pushpa Joshi; Stephan Zierz
Journal:  J Neurol       Date:  2008-03-14       Impact factor: 4.849

8.  Similarity of polygenic profiles limits the potential for elite human physical performance.

Authors:  Alun G Williams; Jonathan P Folland
Journal:  J Physiol       Date:  2007-09-27       Impact factor: 5.182

9.  AMPD1 polymorphism and response to regadenoson.

Authors:  Rayan Saab; Aline N Zouk; Ronald Mastouri; Todd C Skaar; Santosh Philips; Rolf P Kreutz
Journal:  Pharmacogenomics       Date:  2015-11-10       Impact factor: 2.533

10.  Genetic Influence in Exercise Performance.

Authors:  Juan Del Coso; Alejandro Lucia
Journal:  Genes (Basel)       Date:  2021-04-27       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.